Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

A study of aging mice showed that voluntary exercise over 30 days increased striatal dopamine release and improved motor ...

Fintel reports that on December 8, 2025, Oppenheimer maintained coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a ...

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...

Investor Martin Shkreli's big biotech short position is blowing up after the stock's monumental rally over the past week.

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6, ...

Fintel reports that on December 4, 2025, Maxim Group maintained coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a Buy ...

Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the proposed public offering. The Company intends to use the net proceeds from the proposed offering for the ...

The "Exosome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ResearchAndMarkets.com's offering. The Global Exosome Therapeutics Market, ...